Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )
The Deloitte Technology Fast 50 China program annually recognizes fastgrowing high-tech companies in Technology, Media and Telecommunicationsrelated industries (TMT) based on their average revenue growth rates over thelast three years. At the award ceremony, all the top-tier executives from thefastest-growing technology companies within China network shared theirindustry insight into the big challenges IPO has brought and will continue tobring out to these high-growth enterprises.
Advertisement
The fourth recognition by Deloitte Technology Fast 50 China program isattributed to WuXi's phenomenal growth with a 300 percent revenue increaseduring the previous three years. As a pioneer and leader in rapidly growingpharmaceutical R&D outsourcing service industry in China, the company hasboosted its global presence by IPO on the NYSE in 2007 and the acquisition ofthe US-based AppTec Laboratory Services, Inc. in 2008.
"We credit our growth to the unwavering pursuit of building a fullyintegrated pharmaceutical, biotechnology and medical device R&D serviceplatform," commented Mr. Benson Tsang, Chief Financial Officer of WuXiPharmaTech. "With the completion of our Suzhou GLP drug safety evaluationcenter, we will further broaden our service portfolio and enhance our revenuegrowth. Being named again and again to this prestigious honor is a testamentto our commitment to providing high-quality and value-added services to ourclients."
Ranked the 22nd, 27th, 28th and 41st in 2005, 2006, 2007, and 2008,respectively, WuXi PharmaTech is one of the three companies that have won theaward for four consecutive years.
About WuXi PharmaTech
WuXi PharmaTech is a leading pharmaceutical, biotechnology and medicaldevice R&D outsourcing company, with operations in China and the United States.As a research-driven and customer-focused company, WuXi PharmaTech providespharmaceutical, biotechnology and medical device companies a broad andintegrated portfolio of laboratory and manufacturing services throughout thedrug and medical device R&D process. WuXi PharmaTech's services are designedto assist its global partners in shortening the cycle and lowering the cost ofdrug and medical device R&D. The operating subsidiaries of WuXi PharmaTech areknown as WuXi AppTec. For more information, please visit:http://www.wuxiapptec.com.For more information, please contact: Sherry Shao WuXi PharmaTech (Cayman) Inc. Tel: +86-21-5046-4002 Email: [email protected]
SOURCE WuXi PharmaTech (Cayman) Inc.
